Verona Pharma Plc ADR [VRNA] stock prices are down -0.23% to $17.22 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRNA shares have gain 2.50% over the last week, with a monthly amount drifted -6.41%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, PDUFA Target Action Date for ensifentrine of June 26, 2024.
From an analyst’s perspective:
On August 26, 2022, Piper Sandler initiated with a Overweight rating and assigned a price target of $31 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $25 on September 13, 2021. Jefferies initiated its recommendation with a Buy and recommended $17 as its price target on August 25, 2020. Canaccord Genuity started tracking with a Buy rating for this stock on August 10, 2020, and assigned it a price target of $17. In a note dated April 18, 2019, BTIG Research initiated an Buy rating and provided a target price of $17 on this stock.
The stock price of Verona Pharma Plc ADR [VRNA] has been fluctuating between $11.83 and $23.81 over the past year. Currently, Wall Street analysts expect the stock to reach $28.6 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $17.22 at the most recent close of the market. An investor can expect a potential return of 66.09% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at -0.78% with Operating Profit Margin at -133.51%, Pretax Profit Margin comes in at -109.46%, and Net Profit Margin reading is -110.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.19 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.71 points at the first support level, and at 16.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.04, and for the 2nd resistance point, it is at 18.86.
Verona Pharma Plc ADR [VRNA] reported earnings per share of -$0.18 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.28/share, meaning a difference of $0.1 and a surprise factor of 35.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.08 per share as compared to estimates of -$0.29 per share, a difference of $0.21 representing a surprise of 72.40%.
Ratios To Look Out For
It’s worth pointing out that Verona Pharma Plc ADR [NASDAQ:VRNA]’s Current Ratio is 30.68. As well, the Quick Ratio is 30.68, while the Cash Ratio is 28.56. Considering the valuation of this stock, the price to sales ratio is 2992.54, the price to book ratio is 5.22.
Transactions by insiders
Recent insider trading involved Rickard Kathleen A., Chief Medical Officer, that happened on Feb 05 when 36248.0 shares were sold. Director, Edwards Martin completed a deal on Nov 20 to buy 33736.0 shares. Meanwhile, Director EBSWORTH DAVID R bought 0.16 million shares on Nov 06.
